Cubist Systematic Strategies LLC Purchases 63,066 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)

Cubist Systematic Strategies LLC boosted its position in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 27.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 293,675 shares of the biopharmaceutical company’s stock after purchasing an additional 63,066 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Revance Therapeutics were worth $893,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in RVNC. Natixis bought a new stake in shares of Revance Therapeutics during the 4th quarter valued at $31,000. Two Sigma Securities LLC bought a new stake in shares of Revance Therapeutics during the 4th quarter valued at $35,000. Alpine Global Management LLC bought a new stake in shares of Revance Therapeutics during the 4th quarter valued at $37,000. RPO LLC bought a new stake in shares of Revance Therapeutics during the 4th quarter valued at $55,000. Finally, Ameriprise Financial Inc. lifted its position in shares of Revance Therapeutics by 54.1% during the 4th quarter. Ameriprise Financial Inc. now owns 23,706 shares of the biopharmaceutical company’s stock valued at $72,000 after acquiring an additional 8,326 shares during the period. 97.70% of the stock is currently owned by institutional investors.

Revance Therapeutics Price Performance

Shares of RVNC stock opened at $3.65 on Thursday. Revance Therapeutics, Inc. has a twelve month low of $2.30 and a twelve month high of $6.65. The company has a market cap of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90. The business has a fifty day simple moving average of $3.65 and a 200 day simple moving average of $3.72.

Analysts Set New Price Targets

A number of research firms have recently weighed in on RVNC. StockNews.com began coverage on Revance Therapeutics in a research report on Tuesday. They set a “hold” rating for the company. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Eight analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $8.45.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.